Conditions that suppress the immune system, such as HIV/AIDS or certain cancers, can increase this risk
View image online ( Patient holding injectable Use of GLP-1 receptor agonistswith or without glucose-dependent insulinotropic polypeptide (GIP)may be associated with improved clinical outcomes in patients with Type 1 diabetes, according to a large retrospective analysis published in Diabetes Technology & Therapeutics
Discover how it affects weight loss, side effects, and your health when taking this GLP-1 medication
Some people may experience temporary side effects after highdose injections, such as mild headache, nausea, or local skin reactions
Researchers seeking premium standards, dependable sourcing, and trusted peptide consistency increasingly choose providers committed to peptide excellence
Research access for verified customers 21+ access only